Persistent sexual arousal syndrome: a case report and review of the literature.
This article describes a case of persistent sexual arousal syndrome (PSAS) seen by the Gynecology Consult Service of the National Institutes of Health. This syndrome was first described in 2001 and is characterized by excessive and unrelenting sexual arousal in the absence of desire. PSAS has only recently come to the attention of the health care community, and its prevalence in the population is not completely known. It is important to report cases of this syndrome in order to help clarify its prevalence, etiology, and prognosis and to determine possible methods of treatment.
Mahoney
Sheila
S
National Institutes of Health, National Institute of Child Health and Human Development, Reproductive Biology and Medicine Branch, Bethesda, Maryland 0892-1109, USA. manoneys@mail.nih.gov
Zarate
Carlos
C
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy; D003511:Cyclohexanols / Q000009:adverse effects*; D003863:Depression / Q000188:drug therapy; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D009948:Orgasm / Q000187:drug effects; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced* / Q000175:diagnosis; D013577:Syndrome; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride